Nasdaq

SCYNEXIS Resumes Dosing in Phase 3 MARIO Study Following FDA Hold, Triggering $10M Milestone Payment Dispute with GSK

SCYNEXIS, Inc. has announced the resumption of patient dosing in the Phase 3 MARIO study of ibrexafungerp, an oral antifungal medication, following the lifting of a clinical hold by the FDA. This ...
Hosted on MSN

Scynexis resumes dosing in Phase III MARIO study after lengthy delay

Scynexis has resumed dosing of its vaginal yeast infection drug Brexafemme (ibrexafungerp) in a Phase III trial after a 19-month clinical hold by the US Food and Drug Administration (FDA). The ...
Seeking Alpha

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study

Resumption of dosing in this study triggers a $10M milestone payment from GSK plus an additional $20M milestone due in six months; as previously disclosed GSK disputes these milestone payments, and ...
Seeking Alpha

SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study

SCYNEXIS (SCYX) to receive a $22 million payment as part of the resolution related to the restart of the Phase 3 MARIO study on invasive candidiasis Scynexis will promptly wind-down and terminate the ...
Nasdaq

SCYNEXIS, Inc. Advances Phase 1 Trial of SCY-247 Antifungal and Prepares for Phase 3 MARIO Study Restart

SCYNEXIS, Inc. is progressing on its second-generation antifungal SCY-247, having initiated a Phase 1 trial in December 2024, with results expected in Q3 2025. The company also plans to present data ...